Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine

Vaccine

Volumn 26, Issue 44, 2008, Pages 5554-5561

  Airhart, Christina L ^a   Rohde, Harold N ^a   Hovde, Carolyn J ^a   Bohach, Gregory A ^a   Deobald, Claudia F ^a   Lee, Stephen S ^a   Minnich, Scott A ^a  

^a UNIVERSITY OF IDAHO   (United States)

Author keywords

Pneumonic plague; Vaccine

Indexed keywords

ADJUVANT; CRX 524; CRX 527; GLUCOSAMINIDE 4 PHOSPHATE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; LIPID A; PLAGUE VACCINE; PROTOLLIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; LD 50; NONHUMAN; PLAGUE; PRIORITY JOURNAL; RAT; TH1 CELL; YERSINIA PESTIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSAMINE; HUMANS; LIPID A; MALE; MICE; MICE, INBRED BALB C; MOLECULAR MIMICRY; PLAGUE; PLAGUE VACCINE; RATS; RATS, SPRAGUE-DAWLEY; TOLL-LIKE RECEPTOR 4; YERSINIA PESTIS;

EID: 52949136294     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.007     Document Type: Article

References (51)

1. Perry R.D., and Fetherston J.D. Yersinia pestis-etiological agent of plague. Clin Microbiol Rev 10 (1997) 35-66
2. Welkos S., Pitt M.L.M., Martinez M., Friedlander A.M., Vogel P., and Tammariello R. Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. Vaccine 20 (2002) 2206-2214
3. Russell P., Eley S.M., Hibbs S.E., Manchee R.J., Stagg A.J., and Titball R.W. A comparison of plague vaccine USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 13 (1995) 1551-1556
4. Andrews G.P., Heath D.G., Anderson Jr. G.W., Welkos S.L., and Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64 6 (1996) 2180-2187
5. Glynn A., Freytag L.C., and Clements J.D. Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens. Vaccine 23 (2005) 1957-1965
6. Williamson E.D., Stagg A.J., Eley S.M., Taylor R., Green M., Jones S.M., et al. Kinetics of the immune response to the (F1 + V) vaccine in models of bubonic and pneumonic plague. Vaccine 25 6 (2007) 1142-1148
7. Uddowla S., Freytag L.C., and Clements J.D. Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens. Vaccine 25 (2007) 7984-7993
8. Goodin J.L., Nellis D.F., Powell B.S., Vyas V.V., Enama J.T., Wang L.C., et al. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. Protein Exp Purif 53 (2007) 63-79
9. Anderson G.W., Heath D.G., Bolt C.R., Welkos S.L., and Friedlander A.M. Short- and long-term efficacy of single dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 58 6 (1998) 793-799
10. Weeks S., Hill J., Friedlander A.M., and Welkos S. Anti-V antigen antibody protects macrophages from Yersinia pestis-induced cell death and promotes phagocytosis. Microb Pathog 32 (2002) 227-237
11. Abramov V.M., Khlebnikov V.S., Vasiliev A.M., Kosarev I.V., Vasilenko R.N., Kulikova N.L., et al. Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-γ receptor. J Proteome Res 6 (2007) 2222-2231
12. Sing A., Rost D., Tvardovskaia N., Roggenkamp A., Wiedemann A., Kirschning C.J., et al. Yersinia V-antigen exploits Toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 196 8 (2002) 1017-1024
13. Du Y., Rosqvist R., and Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect Immun 70 3 (2002) 1453-1460
14. Mueller C.A., Broz P., Müller S.A., Ringler P., Erne-Brand F., Sorg I., et al. The V-antigen of Yersinia forms a distinct structure at the tip of the injectisome needles. Science 310 5748 (2005) 674-676
15. Overheim K.A., DePaolo R.W., DeBord K.L., Morrin E.M., Anderson D.M., Green N.M., et al. LcrV plague vaccine with altered immunomodulatory properties. Infect Immun 73 8 (2005) 5152-5159
16. Anderson Jr. G.W., Heath D.G., Bolt C.R., Welkos S.L., and Friedlander A.M. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 58 6 (1998) 793-799
17. Williamson E.D., Flick-Smith H.C., Waters E., Miller J., Hodgson I., Le Butt C.S., et al. Immunogenicity of the rF1 + RV vaccine for plague with identification of potential immune correlates. Microb Pathog 42 (2007) 11-21
18. Wang S., Heilman D., Liu F., Giehl T., Joshi W., Huang X., et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 22 (2004) 3348-3357
19. Anderson G.W., Leary S.E., Williamson E.D., Titball R.W., Welkos S.L., Worsham P.L., et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-positive and -negative strains of Yersinia pestis. Infect Immun 64 (1996) 4580-4585
20. Jones S.M., Day F., Stagg A.J., and Williamson E.D. Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine 19 (2001) 358-366
21. Khajuria A., Gupta A., Malik F., Singh S., Singh J., Gupta B.D., et al. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg. Vaccine 25 (2007) 4586-4594
22. Smiley S.T. Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines 7 2 (2008) 209-221
23. Jones T., Adamovicz J.J., Cyr S.L., Bolt C.R., Bellerose N., Pitt L.M., et al. Intranasal Protollin™/V1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 24 10 (2006) 1625-1632
24. Reed D.S., and Martinez M.J. Respiratory immunity is an important component of protection elicited by subunit vaccination against pneumonic plague. Vaccine 24 13 (2006) 2283-2289
25. Glynn A., Roy C.J., Powell B.S., Adamovicz J.J., Freytag L.C., and Clements J.D. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun 73 8 (2005) 5256-5261
26. Brubaker R.R. Interleukin-10 and inhibition of innate immunity to yersiniae: roles of Yops and LcrV (V-antigen). Infect Immun 71 (2003) 3673-3681
27. Rebeil R., Ernst R.K., Gowen B.B., Miller S.I., and Hinnebusch B.J. Variation in lipid A structure in the pathogenic yersiniae. Mol Microbiol 52 5 (2004) 1363-1373
28. Montminy S.W., Khan N., McGrath S., Malkowicz M.J., Sharp F., Conlan J.E., et al. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat Immunol 112 (2006) 521-530
29. Cluff C.W., Baldridge J.R., Stover A.G., Evans J.T., Johnson D.A., Lacy M.J., et al. Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 73 5 (2005) 3044-3052
30. Baldridge J.R., McGowan P., Evans J.T., Cluff C., Mossman S., Johnson D.J., et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 4 7 (2004) 1129-1138
31. Stover A.G., Da Silva Corriea J., Evans J.T., Cluff C.W., Elliott M.W., Jeffery E.W., et al. Structure-activity relationship of synthetic Toll-like receptor 4 agonists. J Biol Chem 279 6 (2004) 4440-4449
32. Airhart C.L., Rohde H., Bohach G.A., Hovde C.H., Deobald C.F., Lee S.S., et al. Induction of innate immunity by lipid A mimetics increases survival from pneumonic plague. Microbiology 154 7 (2008) 2131-2150
33. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., et al. Defective LPS signaling in C3H/HeJ and C57Bl/10ScCr mice: mutation in Tlr4 gene. Science 282 (1998) 2085-2088
34. Reed L.J., and Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 27 3 (1938) 493-497
35. Geary NL. Animal models and correlates of protection for plague vaccines In: FDA Heath and Human Services Public Workshop on Animal Models and Correlates of Protection for Plague Vaccines. Gaithersburg, Maryland: FDA-Center for Biologics Evaluation and Research, 2004: p. 1-300.
36. Lathem W.W., Crosby S.D., Miller V.L., and Goldman W.E. Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc Natl Acad Sci USA 102 49 (2005) 17786-17791
37. Parent M.A., Wilhelm L.B., Kummer L.W., Szaba F.M., Mullarky I.K., and Smiley S.T. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect Immun 74 6 (2006) 3381-3386
38. Bubeck S.S., Cantwell A.M., and Dube P.H. Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect Immun 75 6 (2007) 697-705
39. Human plague in 2002 and 2003. Wkly Epidem Record 2004;79(33):301-8.
40. Honko A.N., Sriranganathan N., Lees C.J., and Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 72 (2006) 1113-1120
41. Alpar H.O., Eyles J.E., Williamson E.D., and Somavarapu S. Intranasal vaccination against plague, tetanus, and diphtheria. Adv Drug Deliv Rev 51 (2001) 173-201
42. Gessener J.E., Heiken H., Tamm A., and Schmidt R.E. The IgG Fc receptor family. Ann Hematol 76 (1998) 231-248
43. Unkeless J.C., and Eisen H.N. Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages. J Exp Med 142 (1975) 1520-1533
44. Snapper C.M., and Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236 (1987) 944-947
45. Heusser C.H., Anderson C.L., and Grey H.M. Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med 145 (1977) 1316-1327
46. Sugai T., Mori M., Nakazawa M., Ichino M., Naruto T., Kobayashi N., et al. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine. Vaccine 23 46/47 (2005) 5450-5456
47. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 6 2 (2007) 133-140
48. Crosbie E.J., and Kitchener H.C. Cervarix-a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. Expert Opin Biol Ther 7 3 (2007) 391-396
49. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., and Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316 (2007) 1628-1632
50. Kawakami K. Promising immunotherapies with Th1-related cytokines against infectious diseases. J Infect Chemother 9 3 (2003) 201-209
51. Lembo A., Pelletier M., Iyer R., Timko M., Dudda J.C., West T.E., et al. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol 108 (2008) 7574-7581